NASDAQ:VTGN VistaGen Therapeutics Q4 2026 Earnings Report $0.24 +0.01 (+2.74%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.24 +0.01 (+2.08%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast VistaGen Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.34Beat/MissMissed by -$0.03One Year Ago EPS-$1.67VistaGen Therapeutics Revenue ResultsActual Revenue$0.47 millionExpected Revenue$0.40 millionBeat/MissBeat by +$65.00 thousandYoY Revenue GrowthN/AVistaGen Therapeutics Announcement DetailsQuarterQ4 2026Date6/15/2026TimeBefore Market OpensConference Call DateMonday, June 15, 2026Conference Call Time4:00PM ETUpcoming EarningsVistaGen Therapeutics' Q2 2027 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) VistaGen Therapeutics Earnings HeadlinesVistaGen Stockholders Reaffirm Board, Governance and OversightSeptember 11, 2026 | tipranks.comVistagen to Present at Psych Congress 2026September 10, 2026 | globenewswire.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 20 at 1:00 AM | Paradigm Press (Ad)Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAugust 14, 2026 | globenewswire.comVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAugust 6, 2026 | globenewswire.comSRX Global (NYSE American: SRXH) Acquires Stake in Vistagen TherapeuticsAugust 4, 2026 | markets.businessinsider.comSee More VistaGen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email. Email Address About VistaGen TherapeuticsVistaGen Therapeutics (NASDAQ:VTGN) (NASDAQ: VTGN), formerly known as VistaGen Therapeutics, is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The company’s research centers on neuroactive nasal spray medicines designed to act rapidly and potentially avoid some of the systemic side effects associated with conventional treatments. Vistagen’s lead product candidate is fasedienol, also known as PH94B, an investigational nasal spray being developed for anxiety-related disorders, including social anxiety disorder. The company is also advancing PH10, an intranasal neuroactive drug candidate being studied for depressive disorders, and PH80, a nasal spray candidate investigated for conditions such as migraine. These products remain investigational and have not been approved for commercial use. Vistagen’s product candidates originated from research involving pherines, synthetic neuroactive compounds intended to influence neural pathways through the nasal cavity. The company is headquartered in South San Francisco, California, and its development activities are primarily focused on the U.S. market. Vistagen is led by President and Chief Executive Officer Shawn K. Singh.View VistaGen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
